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Abstract 
Rationale: Traumatic brain injury (TBI) leads to neurological impairment, with no satisfactory 
treatments available. Classical ketogenic diets (KD), which reduce reliance on carbohydrates and provide 
ketones as fuel, have neuroprotective potential, but their high fat content reduces compliance, and 
experimental evidence suggests they protect juvenile brain against TBI, but not adult brain, which would 
strongly limit their applicability in TBI. 
Methods: We designed a new-KD with a fat to carbohydrate plus protein ratio of 2:1, containing 
medium chain triglycerides (MCT), docosahexaenoic acid (DHA), low glycaemic index carbohydrates, 
fibres and the ketogenic amino acid leucine, and evaluated its neuroprotective potential in adult TBI. 
Adult male C57BL6 mice were injured by controlled cortical impact (CCI) and assessed for 70 days, 
during which they received a control diet or the new-KD. 
Results: The new-KD, that markedly increased plasma Beta-hydroxybutyrate (β-HB), significantly 
attenuated sensorimotor deficits and corrected spatial memory deficit. The lesion size, perilesional 
inflammation and oxidation were markedly reduced. Oligodendrocyte loss appeared to be significantly 
reduced. TBI activated the mTOR pathway and the new-KD enhanced this increase and increased histone 
acetylation and methylation. 
Conclusion: The behavioural improvement and tissue protection provide proof of principle that this 
new formulation has therapeutic potential in adult TBI. 
Key words: Adult traumatic brain injury, epigenetic modifications, ketogenic diet, neurological outcome, 
neuroprotection 
Introduction 
Traumatic brain injury (TBI) is a leading cause of 
death and disability worldwide [1]. The primary 
injury leads to tissue disruption, loss of neuronal and 
non-neuronal cells, neuroinflammation, oxidative 
stress, and brain dysconnectivity [2]. These changes 
underlie the functional sensorimotor and cognitive 
deficits seen post-trauma. At present there is no 









the risk of neurodegenerative diseases, such as 
dementia [3] and is also associated with the risk of 
developing post-traumatic epilepsy [4]. 
In parallel with brain structure disruption, TBI 
leads to altered cerebral energy metabolism. Under 
normal conditions, glucose is the main energy- 
producing source in the brain. TBI leads to an acute 
glucose hypermetabolism [5], followed by a 
prolonged cerebral glucose hypometabolism. Under 
these conditions, the brain can switch to the use of an 
alternative fuel, such as ketone bodies (KB) [5]. KB, i.e. 
ß-hydroxybutyrate, acetoacetate and acetone, are 
synthesized from fatty acids in the liver. KBs can be 
produced under conditions of caloric restriction or 
during use of ketogenic diets (KDs). KDs are 
characterised by a high fat and low carbohydrate 
content, and their use leads to the development of a 
state of ketosis, i.e. increase in plasma and tissue KB 
levels [6]. The KD dietary concept was first developed 
in the 1920s as a therapy for epilepsy and has been in 
clinical use worldwide as a non-pharmacological 
treatment option for treatment-resistant epilepsy [7]. 
KD-based interventions are well- established in 
pediatric epilepsy [8] but less so in adult epilepsy [9]. 
They have significant efficacy in reducing seizures, 
but these fat-rich diets have low palatability and can 
lead to adverse effects, such as tiredness, excessive 
thirst, kidney stones and constipation, which 
significantly reduce patient compliance [10]. 
Apart from epilepsy, KD interventions have 
been shown to have neuroprotective potential in a 
variety of other neurological indications [9, 11, 12]. 
However, in TBI the experimental evidence generated 
in rodents so far with classical KD (with ratios of fat to 
protein and carbohydrate of 4:1 or higher), suggests 
that the neuroprotective effect of such an intervention 
would be limited to the protection of the juvenile 
brain only [13-15]. 
In the present study, we tested a new-KD 
formulation in an experimental model of TBI, the 
controlled cortical impact (CCI) model, in adult mice. 
The new-KD formulation contained medium-chain 
triglycerides (MCT) and also the long-chain 
polyunsaturated fatty acid docosahexaenoic acid 
(DHA), which has been shown to have intrinsic 
neuroprotective properties in TBI [16, 17]. It also 
contained low glycaemic index carbohydrates, fibres, 
and the ketogenic amino acid leucine, with a resulting 
overall ratio of fat to protein and carbohydrate of 2:1. 
We hypothesised that this composition would 
increase the neuroprotective effect of the diet, while 
maintaining its ketogenic potential and also 
increasing its palatability and reducing the adverse 
effects of the classical KD for more compliant use in 
patients. As the energy demise after TBI occurs very 
rapidly, we fed the animals this diet immediately after 
injury and maintained them on it for 70 days, while 
monitoring their recovery. We show that this new-KD 
formulation improves several aspects of neurological 
outcome and significantly counters the tissue damage 
and the increased inflammation and oxidation 
triggered by injury, and thus we present the first 
experimental evidence that a KD designed this way 
could confer neuroprotection in adult TBI. 
Materials and Methods 
Animals 
A total of 30 adult, 10-12 week-old male 
C57BL/6 mice, weighing 22-27 g (Charles River 
Laboratories, Margate, UK), were housed in groups of 
five, maintained the same throughout the study, in 
Individually Ventilated Cage (IVC; Allentown 
Europe, UK), in a 12 h light-dark cycle, with 
controlled room temperature (21 ± 1 °C) and relative 
humidity (40-60%) and with diet and water ad 
libitum. Health screens provided by the vendor 
indicated that animals were free of known pathogens 
in accordance with FELASA guidelines. A 7-day 
acclimatization phase occurred prior to the study. 
Food intake and body weight were monitored daily. 
All animal procedures were carried out under a 
Project Licence approved by the Animal Welfare and 
Ethical Review Body, at Queen Mary University of 
London and the UK Home Office, in accordance with 
the EU Directive 2010/63/EUT. 
Controlled cortical impact model 
A controlled cortical impact (CCI) TBI model 
was used, as previously [18]. After 1-week 
acclimatisation, mice were anaesthetized using 
ketamine (50 mg/kg) and medetomidine (0.5 mg/kg; 
i.p.). Mice were placed in a stereotaxic frame and a 
midline longitudinal incision was performed to 
expose the skull. A right lateral craniotomy was 
carried out using a pneumatic drill, 2.0 mm behind 
bregma and 2.5 mm lateral to the midline. CCI injury 
was induced using the following settings: a 3 mm 
impactor tip with a speed of 3 m/s, a depth of 2.2 mm 
and a dwell time of 100 ms, applied using the PCI3000 
Precision Cortical Impactor™ (Hatteras Instruments, 
Inc., US). A control group underwent craniotomy 
only. After injury, the skull flap was placed back, to 
allow for expansion, and the skin was sutured. Mice 
were allowed to recover in an incubator (37°C) until 
fully awake and active. Buprenorphine (0.05 mg/kg, 
s.c.) was used in all animals pre-operatively for 
pre-emptive analgesia and post-operatively every 12 
h for 3 days post-surgery. 






Following CCI, mice were randomized into two 
groups and fed with a control diet (‘CCI- Control’; 
n=10) or with the new preparation of a ketogenic diet 
(KD) (‘CCI-KD’; n=10) for 70 days (detailed 
composition in Table 1). The craniotomy group were 
fed with control diet (craniotomy; n=10). The diets 
were formulated by Danone Nutricia Research 
(Utrecht, The Netherlands) and manufactured by 
Ssniff (Soest, Germany). The caloric value of the 
control and new diet were 377 kcal/100g and 626 
kcal/100g, respectively. The comparison between this 
diet and various other diets with variable ratios fat: 
carbohydrate and protein is shown in Table S1. Diets 
were stored at -20 °C to prevent lipid peroxidation, 
and fresh diet was given daily. No significant 
differences were seen in the body weight (Figure S1A) 
and food intake curves between the various 
experimental groups, throughout the study. All the 
behavioural work (the primary study endpoint) and 
tissue analysis, was assessed in “blind”, with the 
researcher unaware of the treatment, in accordance 
with the ARRIVE guidelines [19]. 
Experimental design and Behavioural testing 
The testing carried out on various days 
post-injury (dpi) is summarised in Figure S1B. Sample 
size was estimated using power analysis (https:// 
eda.nc3rs.org.uk/eda/) for pairwise post-hoc 
comparisons after ANOVA, at a statistical power of 
90%, with a significance level α < 0.05. 
Modified Neurological Severity Score (mNSS) 
The mNSS was used as previously [20, 21], using 
a scoring based on the ability to perform ten tasks that 
evaluate motor ability, balance and alertness (Figure 
S2A). For each performance criterion, the animal can 
receive a score of 0 (no deficit) or 1 (deficit observed), 
on occasions 0-3 for increasing severity of deficit. The 
first mNSS was obtained 24 h after TBI. During the 
first week, testing was performed every other day, 
then once a week, until the end of the experiment. 
Rotarod 
The Rotarod test (Ugo Basile, France; 3 cm 
diameter) was used for the evaluation of motor 
coordination and balance. Prior to surgery, mice were 
trained on the Rotarod for three consecutive days. The 
first two trials were 60 s each, at 3 rpm, followed by a 
single trial at accelerating speed (3 to 20 rpm over 300 
s, with intervals of at least 25 min rest). The rest of the 
training days consisted of one trial at 3 rpm followed 
by two accelerating trials. The latency to fall from the 
Rotarod was recorded. The average of all accelerating 
phase scores was considered as the baseline 
(pre-injury score). Mice were tested during day 1-3 
post- injury, in three trials a day, using the 
accelerating mode. 
 
Table 1. Composition of the experimental diets; control (cont.) 
vs. the new ketogenic diet (KD) (g/100 g) 
Diet compositions Control New KD 
g / 100g diet g / 100g diet 
Fats 
Soy oil 1.90  
Corn oil 2.20  
Coconut oil 0.90 4.40 
Tuna oil  5.70 
Palm oil  39.90 
Rapeseed oil  5.70 
MCT oil  1.30 
Proteins 
Caseine (85%) 14.00 18.70 
L-Cystine 0.18 0.30 
L-Leucine  1.90 
Carbohydrates 
Cornstarch, pre-gelatinized 45.59  
Maltodextrin, 10 DE 15.50  
Sucrose 10.00  
Galactose  1.50 
Isomaltulose  2.72 
Fibres 
Cellulose powder 5.00 5.00 
Fructooligosaccharides 5.00 
Vits, Mins, Additions 
Mineral & trace element premix 
(AIN-93M-MX) 
3.50 5.83 
    [including 22% Sucrose] 0.77 1.28 
Vitamin mix (AIN-93-VX) 1.00 1.67 
   [Including 97% Sucrose] 0.97 1.62 
Choline chloride (50%; 0,434 g / g) 0.23 0.38 
Tert-butylhydroquinone 0.0008 0.0013 
 Control New KD 
mg / 100g diet mg / 100g diet 
Fatty acid compositions 
C-8:0 64.4 897.3 
C-10:0 51.5 699.1 
C-12:0 395.0 2066.6 
C-14:0 154.6 1317.0 
C-16:0 492.4 18064.5 
C-18:0 136.1 2285.2 
C-18:1w9 (OA) 1040.6 19313.1 
C-18:2w6 (LA) 2180.8 5055.2 
C-18:3w3 (ALA) 107.4 527.6 
C-20:5w3 (EPA) 0.0 326.3 
C-22:6w3 (DHA) 0.0 1430.4 
A. Total Fats 5.0 57.0 
B. Total Proteins 12.1 18.1 
C. Total Carbohydratess 71.1 4.2 
D. Total Sucrose from Vits & Mins 1.7 2.9 
Ketogenic ratio [A/(B+C+D)] 1 : 17 2.3 : 1 
Energy (kcal/100g diet) 377 626 
 
Morris Water Maze 
The Morris water maze test (MWM) was used to 
assess memory associated with spatial learning 
between days 13-18 post-CCI. A 100 cm diameter pool 
filled with opaque water at 23 °C was placed inside a 
white tent, ensuring light uniformity, with 4 visible 





cues hung 10 cm from the pool walls and a 11 cm 
diameter Plexiglas resting platform submerged 0.5 cm 
below water level. Swimming performance (e.g. path, 
distance, speed and latency) was tracked using 
software (ANYmaze, Smart, Bioseb, France). A 
learning period of 5 consecutive days (days 13-17 
post-injury) and a probe trial on day 6 (day 18 
post-injury) were used. During the learning period, 
each mouse was subjected to 4 trials a day, in the pool 
divided into 4 virtual quadrants. The position of the 
platform was constant throughout the training 
session, while the starting position on each of the 4 
training trials was changed. If a mouse did not find 
the platform within 60 s, it was guided to it. After 
reaching the platform, mice were allowed to stay 
there for 15 s. During the probe trial, mice were 
allowed to swim for 60 s in the absence of the 
platform, and the time it took to first enter the 
quadrant that had previously hosted the platform, 
was measured. 
BrdU injections 
From day 63 post-injury or craniotomy, and for 7 
sequential days, animals received i.p. injections of 
5-bromo-2-deoxyuridine (BrdU; 50 mg/kg, twice a 
day), to assess cell proliferation. 
Histology and immunohistochemistry 
At day 70 post-TBI, 5 animals from each group 
were deeply anaesthetized with sodium pentobarbital 
(50 mg/kg, i.p.; Sagatal, Rhone Merieux, Harlow, 
UK), and received a transcardiac perfusion with 
phosphate-buffered saline (PBS; 0.01 M, pH 7.4), 
followed by 4% paraformaldehyde (PFA) in 
phosphate buffer (0.1 M, pH 7.4, 4 °C). The brains 
were dissected out, fixed and paraffin-blocked for 
histology and immunohistochemistry (IHC) analyses. 
7 μm sections were deparaffinised and hydrated 
(xylene and ethanol). Sections were subjected to 
antigen retrieval (10 mM citrate buffer, pH 6.0, 30 min 
at 80 °C), then cooled at room temperature. The tissue 
was blocked with 5% normal donkey serum in 0.2% 
Triton X-100 in PBS for an hour, followed by three PBS 
washes. The primary antibodies used were (overnight 
incubation): rat anti-BrdU (1:200; Acris Antibodies 
GmbH, Cat# SM1667PS), rabbit anti- glial fibrillary 
acidic protein (GFAP) (1:800; Dako, Cat# Z0334), goat 
anti-Iba-1(1:800; Wako, Cat# 019-19741) and rabbit 
anti–translocator protein (TSPO) (1:100; Abcam, Cat# 
ab109497), mouse anti- APC (1:50; Millipore, Cat# 
OP80), 8-OHG (1:200; QED bioscience, CAT# 
12501clone 15A3). The secondary antibodies used 
were labelled with Alexa 488 or Alexa 555 (Molecular 
Probes, Leiden, The Netherlands; 1:200), and Hoechst 
33342 stain (Sigma, UK; 1 μg/ml PBS) was used to 
visualize nuclei. Slides were mounted and cover- 
slipped using Vectashield fluorescent mounting 
medium (H-1000; Vector Laboratories, Burlingame, 
CA). For the analysis of NDUFS4 positive cells, we 
used the EnVision™+ System, HRP (DAB) with rabbit 
primary antibodies Kit (Dako, CAT #K4011), Rabbit 
anti- NDUFS4 (1:2000; Abcam, CAT# ab137064). The 
antibody was diluted using diluent with background 
reducing components (Dako, CAT #S3022). 
For calculation of the lesion size, sections of 7 
µm, 200 μm apart and spanning the entire 
rostro-caudal extent of the injured cortex were stained 
with haematoxylin and eosin (H&E). The lesion size 
was measured with ImageJ software (NIH, Bethesda, 
MD, USA) and calculated using the equation: the 
contralateral (non-lesioned) hemisphere size minus 
the injured hemisphere size and divided by the 
contralateral hemisphere size (Swanson et al, 1990). 
The results are expressed as a percentage of 
hemispheric tissue. 
Image capture analysis and processing 
Four sections per animal were stained, per 
antibody. At least 24 fields/section were captured 
peri-lesionally (immediate area around the lesion). 
Images were viewed at ×40 and photographed using a 
Zeiss Axioskop 2 microscope with a Hamamatsu 
camera (C4742-95). Analyses were carried out by 
thresholding and then superimposed on nuclei, for 
co- localization using a dedicated script (JVP 
AutoColourCellCountsRev) in ImageJ (ImageJ 1.50i, 
NIH, Bethesda, Maryland). Quantification of 
microglia morphology was carried out using cell size 
in ImageJ (minimum 20 cells per animal). The soma 
perimeter was measured excluding the processes. A 
Zeiss LSM 710 confocal microscope was used for 
further characterization (ZENlite software; Zeiss, 
Cambridge, UK). Figures were prepared using 
Illustrator software (Adobe Illustrator CS6). 
Brain tissue preparations 
Brain tissue from 5 animals per group were used 
for western blot analysis, phospholipid analysis and 
the H3 Methylation/Acetylation assay. At day 70 
post-TBI, animals were deeply anaesthetized with 
sodium pentobarbital (50 mg/kg, i.p.; Sagatal, Rhone 
Merieux, Harlow, UK), and decapitated. Brains, 
including the cerebellum, were removed and 
dissected using a brain matrix (as shown in Figure 
S2C). The contralateral and ipsilateral hemispheres 
were separated. Tissue was snap frozen and stored at 
-80 °C. 
Western blot analysis 
A cube of the right hemisphere around the lesion 
was dissected and sonicated in RIPA lysis buffer 





(Sigma-Aldrich) complete with Protease Inhibitor 
Cocktail (Sigma-Aldrich), then centrifuged (10,000 x g, 
10 min, 4 °C) and the supernatant was taken. Protein 
concentrations were determined using the Bradford 
assay. Equal amounts of protein (50 µg) were mixed 
with NuPAGE® LDS sample buffer (Thermo Fisher 
Scientific) and dithiothreitol (DTT) and boiled (95 °C, 
10 min), then separated using Mini-Protean TGX Gels, 
10% (Biorad, UK) and electro-transferred onto 
polyvinylidene difluoride membranes (Biotrace). 
Membranes were blocked in 5% non-fat dry milk in 
Tris-buffered saline (pH 7.4), with 0.1% Tween-20 
(Tris-buffered saline–Tween) for 1 h at room 
temperature. The primary antibodies used were: total 
The mammalian target of rapamycin (mTOR Rabbit, 
1:2,000, Cell Signalling product# 2983, Kit Cat# 9862), 
p-mTOR (Ser2448; Rabbit 1:2000; Cell Signalling 
product# 5536, Kit Cat# 9862), phosphorylated p70S6 
Kinase (Ser371; Rabbit; 1:1000; Cell Signalling 
product# 9208, Kit Cat# 9862), all diluted in 5% 
bovine serum albumin solution, and membranes were 
incubated overnight at 4 °C. The primary antibody 
was removed and blots were washed in Tris-buffered 
saline–Tween and incubated (1 h, room temperature) 
in horseradish peroxidase-conjugated secondary 
antibodies (1:10,000; Jackson ImmunoResearch Labs 
Cat# 323-005- 021). Reactive proteins were visualized 
using enhanced chemiluminescence (VWR 
International). 
Optical density was determined using ImageJ 
software (NIH, Bethesda, Maryland). Membranes 
were also incubated with a mouse vinculin 
monoclonal antibody (1:4,000; clone VIN-11-5, Sigma- 
Aldrich Cat# V4505), for normalisation. Protein level 
was expressed as relative optical density, i.e. the 
optical density of the band revealed by the primary 
antibody, divided by the optical density of vinculin in 
the same lane. 
Phospholipid (PL) analysis 
PL analysis was carried out as previously 
described [22]. Lipids were extracted from the 
cerebellum using the method of Folch and colleagues 
[23], with 0.01% (w/v) 2,6-di-tert-butyl- p-cresol 
(butylated hydroxytoluene) as antioxidant. Neutral 
and acidic PLs were isolated from the lipid extract by 
solid-phase extraction using Isolute® bonded phase 
aminopropyl columns (Kinesis Health Technologies, 
Dublin, UK). The various PL, i.e. phosphatidylcholine 
(PC), phosphatidylethanolamine (PE), phosphatidyl-
serine (PS), phosphatidylinositol (PI) and sphingo-
myelin (SM) were separated by thin-layer chromato-
graphy, and the phosphate content measured. The 
results were normalized to 100 mg wet tissue weight. 
H3 Methylation/Acetylation Assay 
Histones were extracted from the contralateral 
hemisphere and were homogenized using the 
EpiQuik total histone extraction kit (# OP-0006, 
EpiGentek, Farmingdale, NY, USA) according to 
manufacturer’s directions. EpiQuik™ Global 
methylation levels of H3K9 (EpiQuikTM Global 
Histone H3K9 Methylation Assay Kit; CAT# 
P-3018-96; Epigentek, NY, USA) and global acetyl 
Histone H3-K9 levels (EpiQuik™ Global Acetyl 
Histone H3-K9 Quantification Kit CAT# P-4010-96; 
Epigentek, NY, USA) were determined using a 
colorimetric ELISA assay as per manufacturer’s 
protocols. Absorbance was measured using a 
spectrophotometer (450 nm wavelength) with a 
CLARIOstar® microplate reader and MARS software, 
and the acetylation and methylation calculated 
accordingly, with reference to the standard. 
Beta-hydroxybutyrate (β-HB) analysis in 
plasma 
Blood samples were collected (n=10/group) 
through intracardiac sampling, plasma was prepared 
by centrifugation (12,000 x g for 5 min) and samples 
were separated into aliquots. ß- HB was analysed in 
plasma using the Beta-Hydroxybutyrate Assay Kit 
(#MAK041; Sigma Aldrich, MO, USA). The assay was 
performed according to the manufacturer’s 
instructions, with all samples in duplicate. To avoid 
the presence of interfering substances in the plasma 
samples, all proteins were filtered out 
(deproteinized), using a 10 kDa mw cut-off spin filter. 
A β-HB standard curve was generated in parallel. 
Data analysis 
Statistical analysis was performed using 
GraphPad Prism 8 (GraphPad Software, San Diego, 
USA). Data was expressed as mean ± sd. Parametric 
data was analysed using unpaired, two- tailed t-test, 
one-way ANOVA or two-way ANOVA, following 
Tukey’s multiple comparisons, except when 
otherwise stated. The level of significance was set to 
p<0.05. All analysis was carried out blind to 
experimental condition. 
Results 
KD supplementation improves sensorimotor 
impairment after CCI 
Following TBI patients suffer from 
heterogeneous and complex neurological 
sensorimotor deficits such as lack of muscle 
coordination, impaired balance, muscle weakness, 
paresis/paralysis, postural imbalance and gait 
disturbance. Sensorimotor impairment was assessed 





with the mNSS and Rotarod tests. TBI led to early 
significant deficit in the mNSS and all groups showed 
a gradual decrease in TBI-induced impairment over 
70 days. However, a significant improvement was 
observed in CCI-KD animals already after 3 days 
post-injury, compared to the CCI-Control group. This 
difference in mNSS was maintained until the end of 
the study (Two-way ANOVA; p < 0.0001, F (2, 28) = 
247.8; Figure 1A). The craniotomy control animals 
showed only a transient impairment. 
The Rotarod revealed better performance in the 
KD-treated animals compared with the control diet 
group at all three time points after injury (Two-Way 
ANOVA; p < 0.0001, F (2,27) = 37.46; Figure 1B). The 
fall latency was significantly higher in the CCI-KD 
animals, compared to CCI-Control animals. The 
craniotomy-control group showed minimal 
impairment in coordination and balance. 
KD improves spatial memory deficits in the 
MWM after CCI 
TBI leads to cognitive deficits in areas such as 
learning, memory and attention. The hippocampus 
plays a key role in the acquisition and processing of 
new memories. A significant hippocampal lesion was 
apparent in control- CCI animals. The spatial memory 
was assessed using the MWM. No significant 
differences were seen between groups during the 
learning/acquisition phase (Figure S2B). CCI led to 
significant impairment in the probe trial; the new-KD 
fed animals showed significantly improved 
performance in the probe trial compared to the 
injured animals fed the control diet. (One-Way 
ANOVA; p = 0.001, F (2, 29) = 8.262; Figure 1C). 
KD significantly elevates the plasma levels of 
ß-hydroxybutyrate after CCI 
It is well-established that classical KDs are 
associated with an induction of ketosis, which can be 
assessed by measuring the β-HB plasma levels. After 
70 days of exposure to the diet, a significantly higher 
plasma β-HB level was detected in the CCI-KD group 
compared to the CCI-Control animals. Craniotomy 
controls did not show detectable levels of plasma 
β-HB in plasma (Unpaired t-test; p =0.0009, F (8, 2) = 
5.709; Figure 2A). 
KD supplemented animals show a significant 
reduction in lesion size, a decrease in an 
oxidation marker and changes in brain PL 
levels 
TBI is associated with rapid loss of grey and 
white matter that contributes to the overall brain 
volume loss seen post-traumatically [24]. TBI-induced 
cell loss is associated with necrosis and apoptosis, 
followed by the removal of cell debris by microglia 
and macrophages. Analysis of the lesion size after 70 
dpi showed a significant loss of tissue, with almost 
total loss of the ipsilateral hippocampus. The 
new-KD-fed mice had a significantly decreased lesion 
size (Unpaired t-test; p = 0.01, F(5, 4) = 2.161; Figure 
2B). 
TBI leads to the generation of oxidative stress 
[25, 26] which we assessed using 8- hydroxy-
guanosine (8-OHG), a nucleic acid oxidation marker. 
TBI led to a high level of oxidative damage in the CCI- 
Control diet group compared to the craniotomy 
group, and there was a significant reduction in the 
new-KD-fed animals (One-Way ANOVA; p = 0.0001, 
F (3, 15) = 227.8; Figure 2C; a-d). 
 
 
Figure 1. Motor function assessments. mNSS (A) and Rotarod (B). (A). Line graph showing the dynamic changes in the total scoring in mNSS, starting on the 24 h after the 
injury and throughout 70 days. From 3 dpi and thereafter, the new-KD fed animals showed a significant improvement compared to the CCI-Control group (Two way 
ANOVA;***p < 0.0001, F(2, 28) = 247.8 followed by Tukey's multiple comparisons test *p<0.05 (3dpi) **p<0.01 (5dpi) ***p<0.001 (7-70dpi)); the craniotomy group showed 
significant improvement from 1 dpi and nearly no deficits after 14 dpi (***p<0.001 compared to CCI-Control). (B). On 1-3 dpi, both CCI-KD and craniotomy mice showed 
marked improvement compared with the CCI-Control mice. Graph of individual replicates with connected lines-represents the means. (Two-Way ANOVA; p<0.0001, F(2, 27) = 
37.46; Tukey's multiple comparisons test: CCI- Control and CCI-KD or craniotomy on dpi 1 (p<0.05, P<0.001 respectively) and on dpi 2-3 (P<0.001). n=10/group. Cognitive 
performance assessment with MWM. (C). A significant increase in the latency to the first entry into the platform-quadrant was seen in CCI-Control animals in the probe 
test compared to the craniotomy group, and this was markedly reduced in the new-KD-treated animals (One-way ANOVA; p = 0.001, F(2, 29) = 8.262; Tukey's multiple 
comparisons test ***P<0.001). On the right-hand side, a representative illustration of the track of an animal from each group, from the release point into the water until its first 
entrance to the platform quadrant. n=10/group. 






Figure 2. ß-hydroxybutyrate plasma levels. (A). Higher levels of ß-hydroxybutyrate (ß-HB) were seen 70 days post injury in the new-KD fed animals compared to injured 
animals fed with control diet; In the craniotomy group ß-HB levels were not detectable (Unpaired t-test; ***p < 0.0009, F(8, 2) = 5.709). n=10/group. Lesion size. (B). Graph 
showing a significant reduction in lesion size in CCI mice treated with the new-KD compared with CCI-Control vs. craniotomy mice, at 70 days post-TBI (Unpaired t-test; p 
=0.01, F(5, 4) = 2.161; **p<0.01) and representative sections stained with H&E showing differences in lesion size. n=5/group. Oxidative stress. (C). Immunohistochemistry 
quantification of 8-OHG positive cells around the lesion border 70 days post-TBI (One-way ANOVA p<0.0001, F(3,15) = 227.8; Tukey's multiple comparisons test ***p <0.001), 
and representative images (a-c). n=5/group. 
 
 
Figure 3. Lipid analysis. (A). Tissue PC and PE levels were reduced following the 
brain injury compared to craniotomy controls. This reduction was 12% (PC) or 8.5% 
(PE) lesser in the new KD group compared with craniotomy controls. Two-way 
ANOVA; lipid factor: ***P<0.0001 F (1, 26) = 73.73 group factor ***P<0.0001 F (2, 
26) = 43.53; Sidak's multiple comparisons test *p<0.05** p<0.01*** p<0.001). (B). 
Tissue PI, PS and SPH levels were decreased following the injury with no major 
differences between control and KD diet. Two-way ANOVA; lipid factor: 
***P<0.0001, F (2, 39) = 202.2, group factor ***P<0.0001, F (2, 39) = 15.12; Sidak's 
multiple comparisons test *p<0.05, **p<0.01). 
 
CCI in mice is associated with a decrease in brain 
PL levels [24]. The analysis of the PL in the cerebellum 
showed that PC and PE levels decreased significantly 
following the injury compared to the craniotomy 
group, whereas in the group fed with KD, the loss in 
PL was reduced. Tissue PC levels were reduced by 
20% in injured animals on the control diet vs. 
craniotomy controls, and this was reduced to 12% in 
the new-KD group compared with craniotomy 
controls. PE levels decreased by 20% in the injured 
animals on the control diet vs. craniotomy-only, while 
after the new-KD the difference vs. craniotomy 
controls was only 8.5%. (Two-way ANOVA, p < 
0.0001; F (2, 26) = 43.53; Figure 3A). Injury also led to 
decreases in PI, PS and SPH (-19%, -15% and -19% vs. 
craniotomy-controls, respectively), but the new-KD 
did not alter these changes (Two-way ANOVA, 
P<0.0001 F (2, 39) = 15.12; Figure 3B). 
KD supplementation leads to a decrease in 
microglia/macrophage activation but does not 
alter the astrocyte response post-injury 
TBI is followed by intense activation of a 
microglia and macrophage response. This activation 
is reflected in morphological changes and is one of the 
hallmarks of TBI pathophysiology [27]. Microglia, the 
resident brain immune cells, undergo a transition 
from a resting state- ramified morphology to an 
amoeboid morphology, which reflects the activated 
state. In the last decade, it has been shown in human 
imaging studies that these cells still show signs of 
activation many years after injury [28]. This 
long-lasting response has also been described in mice 
and non-human primates [29] and is incompletely 
understood. We used the classic microglia/ 
macrophage marker, Iba-1, and the translocator 
protein (TSPO) marker that has been the used 
extensively for imaging microglia activation state [30]. 
TSPO is expressed in the outer mitochondrial 
membrane and is present in low concentrations in the 
healthy brain; it is significantly upregulated in 
response to brain injury. 
The percentage of Iba-1 positive cells out of total 
DAPI, around the lesion was higher in the 
CCI-Control diet group compared to the CCI-KD and 
craniotomy groups. (One-Way ANOVA; p = 0.002, F 
(2, 12) = 10.15; Figure 4A, b, f, j). Moreover, the 
new-KD fed mice showed an overall decrease in the 





percentage of TSPO-positive cells compared to control 
diet- treated CCI animals (One-Way ANOVA; p < 
0.0001, F (2, 12) = 119.3; Figure 4B, c, g, k). 
The co-staining for Iba-1 and TSPO showed a 
significantly lower percentage of double- stained cells 
in the CCI-KD group compared to the CCI-Control 
group (One-Way ANOVA; p < 0.0001, F (2, 12) = 68.56; 
Figure 4C, d, h, l). Next, we explored the microglia/ 
macrophage morphological differences between the 
CCI-Control diet group (predominantly amoeboid), 
the CCI-KD group (less amoeboid) and craniotomy- 
control group (predominantly ramified) by measuring 
cell size. Microglia cells in the CCI-Control diet group 
were significantly bigger compared with the CCI-KD 
diet group (Mann Whitney test p = 0.008; Figure 4D). 
In response to TBI, astrocytes become reactive 
[31]. The astrogliotic reactivity is reflected in both 
proliferation and cell hypertrophy. After a traumatic 
injury, astrocytes can exert both harmful and 
protective effects, e.g. ablation of astrocytes soon after 
brain injury in mice, led to a poorer outcome, 
suggesting an important protective role of astrocytes 
after injury [32, 33]. 
 
 
Figure 4. Neuroinflammatory response 70 days post-TBI. Immunohistochemistry quantification around the lesion border, of (A) % Iba-1 positive cells (One-way ANOVA; p = 
0.0026, F(2, 12) = 10.15; Tukey's multiple comparisons test *p<0.05 **p<0.01) and representative images (b,f,j). (B) TSPO positive cells (One-way ANOVA; p < 0.0001, F(2, 12) = 119.3; 
Tukey's multiple comparisons test ***p<0.001) and representative images (c,g,k). (C) Co-localised TSPO and Iba-1 positive cells (One-way ANOVA; p < 0.0001, F(2, 12) = 68.56; 
Tukey's multiple comparisons test ***p<0.001) and representative images (d,h,l). Note the different microglia morphology (activation): amoeboid vs. ramified. Scale bars=100 µm. 
To show co-localization we enlarged the area marked with a rectangle. Scale bars= 100 µm. (D) Microglia cell size analysis showing the differences in cell size (Mann Whitney test 
**p<0.01) and corresponding images. The insets show the clear morphological differences. Scale bars= 100 µm. n=5/group. 






Figure 5. Astrocytic response 70 days post-injury. Immunohistochemistry quantification around the lesion border, of (A) % GFAP positive cells (One-way ANOVA p < 0.0001, 
F(2, 10) = 118.8; Tukey's multiple comparisons test ***p<0.001) and representative images (b,f,j). (B). % BrdU positive cells (One-way ANOVA p < 0.0001, F(2, 12) = 23.71; Tukey's 
multiple comparisons test **p<0.01***p<0.001) and representative images (c,g,k). (C). Co-localised % GFAP and BrdU positive cells (One-way ANOVA; p < 0.0001, F(2, 10) = 9.652; 
Tukey's multiple comparisons test *p<0.05 **p<0.01) and representative images (d,h,l). n=5/group. 
 
CCI led to an increase in the percentage of the 
positive astrocyte marker- glial fibrillary acidic 
protein (GFAP), out of total DAPI - around the lesion 
border, with no differences between the control diet 
and the new-KD diet groups (One-Way ANOVA; p < 
0.0001, F (2, 10) = 118.8; Figure 5A, b, f, j). 
Additionally, in both diets, after TBI, there was an 
increase in newly- formed astrocytes, i.e. cells double- 
labelled with GFAP and BrdU, at 70 dpi (One-Way 
ANOVA; p = 0.005, F (2, 10) = 9.652; Figure 5C, d, h, l). 
KD supplementation modulates cell 
proliferation after CCI 
TBI is associated with an increase in cell 
proliferation, including an induction of neurogenesis 
[34] [35], processes which are interpreted as repair 
mechanisms. New-born cells are detected not only in 
the neurogenic areas of the brain (such as the sub-
granular zone of the dentate gyrus or the sub-
ventricular zone of the lateral ventricles), but also in 
the perilesional area, and in contralateral hemisphere 
regions such as the hippocampus. The analysis of 
proliferating cells after CCI around the lesion, showed 
a significantly higher percentage of BrdU-positive 
cells compared to the craniotomy group. The 
treatment with KD led to a noticeably increased 
perilesional cell proliferation (One-way ANOVA; p < 
0.0001, F (2, 12) = 23.71; Figure 5B, c, g, k). 
KD supplementation leads to the protection of 
oligodendrocytes after CCI 
Oligodendrocytes are responsible for producing 
myelin and maintaining myelinated fibres in the 
brain. TBI alters the response of both mature 
oligodendrocytes and immature proliferative oligo-
dendrocytes [36]. We show that the CCI injury led to a 
significant reduction in the percentage of oligo-
dendrocytes, labelled with adenomatous polyposis 
coli (APC) out of total DAPI, perilesionally. This 
injury-induced decrease was significantly affected by 





the new-KD (One-Way ANOVA; p = 0.005, F (2, 12) = 
8.563; Figure 6A, b, f, j). In addition, dual staining of 
APC and BrdU showed a higher percentage of 
double-stained APC/BrdU cells in the CCI-KD group 
compared with the two other groups (CCI-Control 
2.4±0.35; CCI-KD 4.1±0.38; Craniotomy 1.4±0.2; One- 
way ANOVA; p = 0.002, F (2, 12) = 18.15; Figure 6B, d, 
h, l). 
KD modulates mTOR signalling and alters the 
mitochondrial marker NDUFS4 levels after 
CCI 
The mammalian target of rapamycin (mTOR) is a 
protein kinase that integrates energy, nutrient and 
growth factor signals to regulate various cellular 
functions, when activated. It is part of two distinct 
multi-protein complexes, mTORC1 and mTORC2. 
The activation of mTOR has been associated with 
repair mechanisms after neural injury [37, 38]. One of 
the downstream signalling effectors in the mTORC1 
pathway is p70S6k (ribosomal protein S6 kinase 
beta-1). There is an increase in the levels of 
phosphorylated mTOR (p-mTOR) in the injured tissue 
and the new-KD further amplified this response to 
injury. Thus, the ratio of p-mTOR/mTOR, at 70 days 
after injury, significantly increased in the CCI-KD 
group compared to both CCI-control and craniotomy 
groups (1.34±0.08 vs. 0.75±0.07 and 0.34±0.05 
respectively; One-Way ANOVA ***p<0.0001, F (2,12) 
= 51.26; Figure 7C). The new-KD also increased the 
level of the mTORC1 downstream effector p70S6k in 
its phosphorylated form at 70 days post injury 
compared to the CCI-Control and craniotomy groups 
(p-mTOR: One-Way ANOVA; p = 0.001, F (2, 11) = 
37.44; Figure 7A, B and p70S6k: One-Way ANOVA; p 
= 0.001, F (2, 7) = 44.72; Figure 7D). 
 
 
Figure 6. Oligodendrocytes. (A). Quantification of oligodendrocytes 70 days post-TBI (APC positive cells) (One-way ANOVA p = 0.005, F(2, 12) = 8.563; Tukey's multiple 
comparisons test **p<0.01 ***p<0.001) and representative images (b,f,j)). (B). Dual staining APC and BrdU (One-way ANOVA p = 0.0002, F(2, 12) = 18.15; Tukey's multiple 
comparisons test *p<0.05 **p<0.01) and representative images (d,h.l). Scale bar=100 µm. n=5/group. 






Figure 7. mTOR pathway. Graph and representative cropped gels of western blot analysis of protein levels of: (A). Phosphorylated mTOR (Ser2448) (289 kDa) (One-way 
ANOVA p < 0.0001, F(2, 11) = 37.44; Tukey's multiple comparisons test **p<0.01, ***p<0.001), (B). Total mTOR; 289 kDa (One-way ANOVA: ns, F(2, 14) = 0.5253; Tukey's multiple 
comparisons test: ns), and (C). Phosphorylated-mTOR/total mTOR ratio. 
 
 
Figure 8. Complex-I mitochondrial marker. (A). Quantification of NDUFS4 
positive cells 70 days post-TBI (One-way ANOVA p = 0.0006, F(2, 9) = 19.18; Tukey's 
multiple comparisons test *p<0.05, **p<0.01 ***P<0.001). Epigenetics markers. 
Quantification of (B). H3K9 Methylation ratio (One-way ANOVA p =0.0004, F(3, 15) = 
11.33; Tukey's multiple comparisons test **p<0.002) and (C). H3K9 Acetylation ratio 
(One-way ANOVA p <0.0001, F(3, 15) = 20.71; Tukey's multiple comparisons test ***p 
<0.001). All measurements were assessed at 70 days post-TBI. n=5/group. 
 
TBI induces acutely a significant mitochondrial 
dysfunction [39]. The protein NADH dehydrogenase 
[ubiquinone] iron-sulfur protein 4 (NDUFS4) is an 
accessory subunit of the mitochondrial membrane 
respiratory chain NADH dehydrogenase (complex I). 
It is a membrane protein located in the inner 
mitochondrial membrane and it is part of the 
mitochondrial respiratory chain that plays a vital role 
in cellular ATP production. At 70 days post-injury we 
detected a marked increase in NDUFS4, and the levels 
of this mitochondrial marker NDUFS4 in the 
perilesional area were reduced in the injured mice 
receiving the new- KD (One-Way ANOVA; p = 0.0006, 
F (2, 9) = 19.18; Figure 8A). 
KD modulates H3K9 methylation and 
acetylation 
In the last decade, evidence has been 
accumulating that ketones can induce epigenetic 
modifications, such as increased histone acetylation 
and DNA methylation [40]. A strong effect of the 
new-KD was observed on both histone H3K9 
methylation and acetylation compared with the CCI- 
Control and craniotomy groups (One-Way ANOVA; p 
= 0.0004, F (3, 15) = 11.33; Figure 8B and One-Way 
ANOVA; p < 0.0001, F (3, 15) = 20.71; Figure 8C 
respectively). 
Discussion and Conclusion 
In this study, we carried out a TBI in adult mice 
using the CCI model - which was previously shown to 
be insensitive in adult animals to ketogenic dietary 
intervention [13] and fed the animals a new-KD for 70 
days post-injury, while assessing the neurological 
outcome. The CCI model involved replacing of the 
bone flap and allowing expansion, therefore the 
observations presented with this new diet can be 
interpreted as reflecting a clinical situation where 
there is control of the acute rise in intracranial 
pressure following a severe injury. We also examined 
the brain tissue at the end of the experiment, for signs 
of neuroprotection. We present evidence that a new 
ketogenic formulation given immediately post TBI in 
adult animals can lead to functional neurological 
benefits and can reduce the injury impact on brain 
tissue. This new preparation has a lower fat to 
carbohydrate and protein ratio, i.e. a ratio of 2:1 vs. a 
ratio of 4:1, which is characteristic of classical KD 
formulations, and includes medium chain 
triglycerides (MCT), docosahexaenoic acid (DHA) 
and leucine. It is also higher in protein, fibres and 





carbohydrates with low glycaemic index, compared 
with the classic KD. 
Intervention with this novel KD formulation 
reduced sensorimotor impairment, including 
coordination and balance, and improved spatial 
memory recovery after injury. Tissue loss post-injury 
is linked to the sensorimotor and cognitive deficits 
seen after injury [41]. The brain lesion size was 
significantly decreased in the new-KD group 
compared to the injured animals on control diet, and 
the PL loss in tissue following injury was also 
attenuated. 
TBI initiates a series of neurochemical events that 
compromise cerebral energy metabolism. This 
metabolic disruption requires high cellular energy to 
reinstate homeostasis. TBI leads to a transient 
“hyperglycolysis” phase (possibly associated with the 
acute post-injury increase in hypoxia-inducible factor 
1-alpha [42]), followed by a prolonged period of 
metabolic depression, during which glucose 
utilisation drops dramatically. Although glucose 
serves as the main metabolic substrate for neurons, it 
has been shown that other energy-producing 
substrates, such as lactate and pyruvate, might be 
utilized by neurons to sustain their activity [15]. In 
addition to glucose metabolism, all cell types in the 
brain are capable to metabolise ketone bodies when 
present, and ketones are capable of fulfilling the 
energy requirements of the brain. Ketosis, reflected in 
elevated β-HB plasma levels, can be achieved by 
following a high-fat, low-carbohydrate classical KD 
that acts as a provider of alternative substrates for 
cerebral energy metabolism [6]. We show here that the 
β-HB plasma levels were significantly higher in the 
injured group fed with the new-KD, emphasising the 
fact that this formulation can lead to a state of ketosis, 
although the ketogenic ratio is lower than in the 
classical KD. The β-HB level we measured is in the 
range reported in previous studies with KD 
formulations in rats and mice [43-45]. 
The new-KD modified the neuroinflammation 
reaction post-injury, i.e. it reduced activated microglia 
peri-lesionally. Numerous studies have reported that 
post-injury changes in the microglia functional state 
are associated with the de novo expression of the 
mitochondrial translocator protein (TSPO). Post-TBI, 
there is an increase in TSPO levels [46, 47]. Here we 
show that injured animals fed with the new-KD had a 
significantly reduced TSPO expression in Iba-1 
expressing cells compared with the injured animals 
fed with a control diet, at 70 days post-CCI. 
One other component of the glial response after 
TBI is represented by astrocytic activation. Astrocytes 
respond to mechanical strain and to the ATP released 
from injured cells at the injury site, which triggers 
astrocyte activation and recruits them to the site of 
injury. In response to a focal injury, reactive astrocytes 
form a scar border that isolates the damaged and 
inflamed tissue from the healthy tissue [48-50]. These 
scar borders are comprised almost entirely of newly 
proliferated astrocytes, which may subsequently 
contribute to tissue repair/regeneration [33, 51]. The 
present study indicates a strong astrocytic activation 
at more than 2 months after injury, as reflected by the 
GFAP marker, and also shows an increase in the 
numbers of newly-born astrocytes even at this late 
time post-injury, but with no differences between the 
control diet and the new-KD treated groups. 
TBI triggers loss of oligodendrocytes and 
demyelination, and there is a relationship between 
white matter loss and post-traumatic cognitive 
impairment [52, 53]. The current findings confirm the 
oligodendrocyte vulnerability after traumatic injury 
and indicate a protection of oligodendrocytes and also 
an increase in the newly formed oligodendrocyte pool 
along the lesion border, by the new-KD. As 
previously shown, CCI leads to a detectable decrease 
in PL species at this time point after injury [54]. The 
new-KD reduced the decrease in PC and PE, but, 
overall, the impact on PL loss in tissue was not as 
marked as the impact of a dietary supplementation 
with a combination of brain phospholipid precursors 
[54]. 
Studies on KD have shown that these fat-rich 
and carbohydrate-poor diets can induce epigenetic 
alterations, and it is interesting to note that epigenetic 
changes such as increased histone acetylation have 
been associated with improved learning and memory, 
while decreased acetylation is associated with 
cognitive impairment such as that seen during ageing 
[55, 56]. Gao and colleagues [57] have reported 
decreases in histone acetylation and methylation after 
TBI in the immature brain. Our new-KD induced a 
marked increase in histone acetylation and in histone 
methylation, therefore it could be suggested that this 
epigenetic modulatory effect might be beneficial 
post-TBI. 
Mitochondrial dysfunction is an early event 
post-trauma, and is a critical determinant of energy 
failure and cellular demise [58]. Mitochondria 
disruption is also a key link to increased oxidative 
stress [59], which appears to be reduced by the new- 
KD in the injured CCI tissue. 
Interestingly, our results show that injury leads 
to an increase in the tissue expression of the 
mitochondrial marker NDUFS4, and the new-KD 
significantly dampened this increase. The knockout of 
NDUFS4 in the heart has been shown to be protective 
in reperfusion injury following heart ischaemia [60]. 
Furthermore, it has been shown that the activation 





state of mitochondrial complex I is linked to 
reperfusion injury and oxidative stress post-ischaemia 
[61]. An improved understanding of the impact of the 
new-KD on brain mitochondria at this time after 
injury and a comprehensive interpretation of these 
first observations on the complex I marker, would be 
greatly aided by functional measures on fresh 
mitochondria isolated from the injured tissue, and a 
characterization of the transitions between 
conformational states (active vs. de-active and 
catalytically dormant) of complex I, as reported in 
recent studies in a murine model of immature 
hypoxia-ischaemia encephalopathy [62]. 
One of the changes reported in studies with KD 
in the context of epilepsy is an inhibition of mTOR 
[63], a signalling pathway whose activation is linked 
to epileptogenesis. It has been suggested that this 
inhibitory effect may be linked to the impact of KD on 
growth and also its anticonvulsant properties. It has 
been shown that TBI leads to a fast activation of 
mTORC1, and suppression of this initial activation 
may be beneficial [64]. We show that CCI in mice led 
in the long-term to an activation of mTOR (as 
reflected in the increase in p-mTOR), and this was 
enhanced by the new-KD, after 70 days of exposure to 
this diet. This enhancement in signalling was 
supported by the observed increase in 
phosphorylated p70S6k. It is tempting to suggest that 
this effect, which is reported for the first time after 
traumatic central nervous system injury, may be 
linked to beneficial effects of mTOR activation on 
compensatory brain plasticity post-injury and 
recovery of cognitive function [65, 66]; effects which 
are thus clearly opposite to the deleterious impact of 
mTOR activation in the acute phase. Although the 
new protein synthesis which would be involved in 
endogenous attempts to restore brain connectivity 
may not be exclusively under the control of mTOR (in 
particular mTORC1), this signalling pathway may still 
make a significant contribution to the reduction of the 
lesion and the inherent brain circuit remodelling 
involved in improved neurological performance. 
Interestingly, an increase in mTOR activation has 
also been reported after chronic exposure to a KD 
treatment which induced neuroprotection in a model 
of optic neuropathy [67]. In the present study, it is 
likely that the addition of leucine to the new-KD may 
have contributed to this effect. It would be interesting 
to assess in future studies whether the early post- 
injury effect of the new diet is to inhibit mTOR, 
whereas in time, the effect becomes opposite, and 
leads to stimulation of mTOR, which supports neuro-
repair. 
Overall, we show evidence in the present study 
that it is possible to characterize significant 
neuroprotective properties of a KD following TBI in 
an adult brain, using a new-KD formulation with a fat 
to carbohydrate and protein ratio which is also likely 
to be associated with an improved tolerability, and 
also enriched in omega-3 fatty acids, in particular, 
DHA, which has been shown to have intrinsic 
neuroprotective value in TBI. With reference to the 
DHA diet content of our new diet (1430 mg/100 g 
diet), it is interesting to note that Pu and collaborators 
[68] administered for 35 days a diet enriched in fish oil 
(4000 mg fish oil/100 g diet, containing DHA and 
eicosapentaenoic acid (EPA); EPA:DHA ratio of 2.6) 
following CCI in mice, and reported improvement in 
tissue protection and in functional outcome after 
injury. As our first exploratory study was focused on 
the proof of principle for the whole diet, it is not 
possible to establish which diet component made the 
most critical contribution to the benefits seen on 
various endpoints, and this will need to be addressed 
with priority in future studies, to refine further the 
composition of the diet and better understand 
mechanistically its mode of action. Future studies 
could help assess whether the beneficial long-term 
effects of the new diet are supported by very early 
neuroprotective mechanisms triggered in the first 
hours or day post-injury by the diet. This is the first 
evidence which suggests that a KD approach could be 
used in human adult TBI, expanding the range of 
potential clinical uses of this dietary KD principle [69] 
in an indication where there is a need to move away 
from glucose as a fuel and also avoid hyperglycaemia 
[70], which is a modifiable risk factor contributing to 
poor outcome in TBI [71]. How this dietary paradigm 
could be implemented post-trauma in the context of 
human TBI, and the exact dietary regime parameters, 
i.e. optimum onset and duration of the intervention, 
remain to be clarified in further studies. 
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